

## Chemocare prescription V1.03

Forename

Surname

## Protocol

PERTUZUMAB+TRASTUZ MAINT

SA (m<sup>2</sup>)

Height (m)

Weight (kg)

DOB

Patient NO

Local No.

Course Name:

### Pertuzumab, Trastuzumab (Maintenance)

Consultant

Ward

7 Type of line

SINGLE LINE

## Diagnosis

Carcinoma of Breast

NHS No

[illegible]

### Additional Prescribing Notes

Patients must be registered with the CDF before commencing treatment.

## Pertuzumab





Pertuzumab has been associated with infusion and hypersensitivity reactions .Close observation of the patient during and for 60 minutes after the first infusion and during and for 30-60 minutes after subsequent infusions is recommended .

Trastuzumab:

MUGA scan required prior to day 1 and then every 4 months during treatment.

For the management of cardio toxicity refer to NCI Guidelines British Journal of Cancer (2009) 100, 684-692

**CAUTION:** Patients should be observed for at least six hours after the start of the first infusion and for two hours after the start of the subsequent infusions for symptoms of hypersensitivity.

Day	Date and Time	Drug and dose (per m2) or dose (per kg)	ACTUAL DOSE	Infusion Fluid and Final Volume	Route	Additives	Time/Infusion Rate	Line	Given/Checked by	Time Start/Stop	Comments	
1	T=hrs	PERTUZUMAB  (420mg)	420  mg	SODIUM CHLORIDE 0.9%  250 ml	IV				 Batch No.		Infuse over 30-60 mins. After infusion observe for 30-60 mins before starting next infusion.	
1	T=:hrs	TRASTUZUMAB  (6mg/kg)	 mg	SODIUM CHLORIDE 0.9%  250 ml	IV		Infuse over 30 Mins at a rate 500 ml/hr		 Batch No.			
Allocated by:			Confirmed by:		Authorised by:		Checked by: (Pharmacist)				Parenteral Intrathecal Oral	1 0 0
Date:			Date:		Date:		Date:					